This novel insight into GLT-1′s modulation of PS1 and Aβ production could lead to new therapeutic strategies targeting Aβ pathology in Alzheimer’s disease. This evidence concerns the gene SLC1A2 and early-onset autosomal dominant Alzheimer disease.